Raju Kapoor

Summary

Affiliation: University College London
Country: UK

Publications

  1. doi request reprint Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N3BG, UK
    J Neurol Sci 274:54-6. 2008
  2. doi request reprint Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
    Raju Kapoor
    Department of Neuroinflammation, National Hospital for Neurology and Neurosurgery and the Institute of Neurology, Queen Square, London, UK
    Lancet Neurol 9:681-8. 2010
  3. doi request reprint Sodium accumulation is associated with disability and a progressive course in multiple sclerosis
    David Paling
    NMR Research Unit, Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    Brain 136:2305-17. 2013
  4. pmc Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability
    David Paling
    Department of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK
    J Cereb Blood Flow Metab 34:34-42. 2014
  5. ncbi request reprint Axonal protection achieved in a model of multiple sclerosis using lamotrigine
    David A Bechtold
    Department of Clinical Neuroscience, King s College London, Guy s Campus, National Hospital for Neurology and Neurosurgery, London, UK
    J Neurol 253:1542-51. 2006
  6. doi request reprint Energy failure in multiple sclerosis and its investigation using MR techniques
    David Paling
    NMR Research Unit, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    J Neurol 258:2113-27. 2011
  7. ncbi request reprint Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Curr Opin Neurol 19:255-9. 2006

Detail Information

Publications7

  1. doi request reprint Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N3BG, UK
    J Neurol Sci 274:54-6. 2008
    ..Clinical trials of neuroprotection using blockers of sodium channels are now under way. There is no agreement yet on several aspects of trial design, but the situation should become clearer once the results of these trials are reported...
  2. doi request reprint Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
    Raju Kapoor
    Department of Neuroinflammation, National Hospital for Neurology and Neurosurgery and the Institute of Neurology, Queen Square, London, UK
    Lancet Neurol 9:681-8. 2010
    ..In this phase 2 trial, we aimed to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with secondary progressive multiple sclerosis...
  3. doi request reprint Sodium accumulation is associated with disability and a progressive course in multiple sclerosis
    David Paling
    NMR Research Unit, Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    Brain 136:2305-17. 2013
    ..Increased total sodium concentration is likely to reflect neuroaxonal pathophysiology leading to clinical progression and increased disability...
  4. pmc Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability
    David Paling
    Department of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK
    J Cereb Blood Flow Metab 34:34-42. 2014
    ..Bolus arrival time was longer in patients with greater disability independent of atrophy and T2 lesion load, suggesting alterations in cerebral arterial hemodynamics may be a marker of clinically relevant pathology. ..
  5. ncbi request reprint Axonal protection achieved in a model of multiple sclerosis using lamotrigine
    David A Bechtold
    Department of Clinical Neuroscience, King s College London, Guy s Campus, National Hospital for Neurology and Neurosurgery, London, UK
    J Neurol 253:1542-51. 2006
    ..5 %+/-38.5; lamotrigine: 10.4 %+/-12.5, P<0.01). The findings suggest that lamotrigine may provide a novel avenue for axonal protection in MS...
  6. doi request reprint Energy failure in multiple sclerosis and its investigation using MR techniques
    David Paling
    NMR Research Unit, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    J Neurol 258:2113-27. 2011
    ....
  7. ncbi request reprint Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design
    Raju Kapoor
    National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Curr Opin Neurol 19:255-9. 2006
    ..This review considers the rationale for different therapeutic strategies for neuroprotection and discusses the controversies of trial design...